Nuvectis Pharma, Inc.
For the period ended Aug 4, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 4, 2026 · Filed Aug 4, 2026
Use the contents to explore the available documents and sections.
NVCT$20.91+17.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Recent Developments
Recent Developments
| · | Completed public offering in July 2026 for gross proceeds of $115 million, which includes the exercise of the underwriters’ overallotment. Transaction was anchored by leading healthcare investors and extends our cash runway into 1H 2029. |
| · | Ciprocopan (NXP100) |
| o | In July 2026, our partner Haisco announced marketing approval of ciprocopan in China for the treatment of patients with PNH previously untreated with complement inhibitors. The marketing application in China for the treatment of PNH patients previously treated with anti C5 therapy is under review. |
| o | U.S. regulatory efforts underway; a pre-investigation new drug (“IND”) meeting with the Food and Drug Administration (“FDA”) followed by IND submission expected in 4Q2026. |
| · | NXP200 |
| o | Phase 1b in China in patients with BRAF-mutated solid tumors is ongoing. |
| o | Oral presentation of additional clinical data generated by Haisco will be presented at the upcoming European Society for Medical Oncology (ESMO) conference (Madrid, Spain, October 23–27, 2026). |
| o | U.S. regulatory efforts underway; IND submission expected in 4Q2026. |
| · | NXP900 |
| o | With the shift in corporate focus towards the development of ciprocopan, the NXP900 clinical development will now continue with the promising, higher potential impact, combination opportunities: |
| § | Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide an update by the end of this year. The initiation of the combination study of NXP900 with lorlatinib (Lorbrena®) in patients with NSCLC ALK+ who initially responded to, and later progressed on, an ALK inhibitor, is expected in 3Q2026. |
| § | Pancreatic cancer: Based on in-bound interest from two leading medical centers in the U.S., an investigator-sponsored trial (IST) is planned to evaluate the combination of NXP900 plus daraxonrasib in patients with pancreatic cancer at these centers. Study initiation is contingent on FDA approval and availability of daraxonrasib. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.